India's Russian oil imports up slightly in January-June, data shows
Reliance Industries
Ltd and Nayara Energy making almost half of the overall purchases from Moscow, according to data provided by sources.
India, the world's third-largest oil importer and consumer, received about 1.75 million barrels per day of Russian oil in January-June this year, up 1% from a year ago, the data showed.
The two private refiners have term deals to buy Russian oil, while state companies rely on purchases from the spot market.
India's purchases of Russian oil sold at discounted rates surged after Western nations imposed sanctions and stopped buying oil from Moscow over its invasion of Ukraine in 2022.
Earlier this week, U.S. President Donald Trump threatened sanctions on buyers of Russian exports unless Moscow agrees a peace deal within 50 days.
Indian refiners expect that any move by Trump is unlikely to disrupt oil supplies but could wipe out the thinning discount on Russian crude, as traditional and new suppliers ramp up output, refinery officials told Reuters.
In January-June, Russia continued to be the top supplier to India, accounting for about 35% of India's overall supplies, followed by Iraq, Saudi Arabia, and United Arab Emirates.
The United States was the fifth-largest oil supplier to India, up from the sixth position it held a year earlier, the data showed.
India plans to raise energy imports from the U.S. as it prepares for a trade deal with Washington to avoid stiff U.S. import tariffs.
Overall, India's oil imports in January-June rose by 4.3% to about 5.2 million bpd, the data showed.
In June, India's Russian oil imports rose 17.4% to about 2 million bpd from the previous month, dragging down the share of Middle Eastern producers and the Organization of the Petroleum Exporting Countries.
Mark Potter
)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
25 minutes ago
- Mint
India has seen an explosion of fertility startups. Next up: deal spree
Bengaluru/Mumbai: India's growing incomes and falling fertility rate have birthed a new breed of startups looking to fill gaps and provide convenience in assisted reproduction services, drawing interest from investors and large healthcare chains. Upstarts such as Luma Fertility and Arva Health offer services ranging from at-home hormone monitoring and assessment to in-vitro fertilization (IVF) at their centres, while Initomakes portable fertility tracking least 37 fertility ventures were founded between 2021 and 2025 in India, raising $86.4 million combined in equity investments, according to Tracxn data. 'What is interesting is that these startups are highly focused on offering services such as fertility testing and egg freezing, apart from conventional fertility offerings…," said Shobhit Agarwal, chief executive officer at Nova IVF Fertility. 'They are well exposed to European markets, understand the changing landscape of the fertility market in India and are helping to bring new allied services to India and create these markets in larger cities." IVF and other fertility solutions have been available in India for decades. Yet demand has grown in recent years as more women decide to have children later and infertility increases. Rising incomes mean a higher number of Indians can access treatment. EY estimates the nation's IVF market to rise from $793 million in 2020 to $1.45 billion by 2027, expanding 15-20% annually. Mumbai-based Luma offers embryo grading, advanced egg quality assessment, egg freezing, IVF, male and female fertility testing and care and a smartphone application to track hormones and record symptoms. Arva provides everything from hormone testing and fertility consultation to IVF and IUI (intra-uterine insemination). Inito sells at-home single-use kits for monitoring hormone levels during fertility cycles–crucial information for couples struggling to conceive. 'Their (new startups') presence has helped expand awareness and convenience, especially for individuals taking early steps toward understanding their reproductive health," said Kshitiz Murdia, chief executive officer and whole-time director of Indira IVF, the country's largest infertility treatment chain. Private investors are taking notice. Last week, Luma, which recently opened a fertility clinic in Mumbai, announced its $4 million fundraise from Peak XV's Surge, Metropolis Healthcare's promoter Ameera Shah and Vijay Taparia of B2V Ventures. In May, Bengaluru-based Arva secured $1 million in pre-seed funding led by early-stage investment firm All In Capital. Expansion plans Inito plans to enter 20 countries, including Australia and Canada, by next year, founder and chief executive officer Aayush Rai told Mint. 'We're a deeptech company, and the idea is to build a global company. The consumption patterns are different in India and outside, with Western countries more open to adopting newer technologies." Inito lastraised $6 million in Series A funding led by Fireside Ventures in November 2023. Luma Fertility, which recently established its first clinic in Mumbai's Bandra area, is looking to launch two more centres in the financial capital, followed by expansion into Bengaluru, Hyderabad, Pune and Gurugram. 'While a majority of it will be organic expansion, we are open to acquisitions to widen the scope of fertility services like in vitro-fertilization (IVF) and egg freezing,"said Neha Motwani, founder of Luma. There are other startups proving support services . BabyReady provides teleconsultation and financial services for couples seeking fertility treatments and Elawoman offers counselling and access to fertility clinics. India IVF, a chain of tech-enabled fertility care centres across India, received pre-Series A funding last year. Veera Health provides treatment for polycystic ovary syndrome or PCOS, which is known to cause infertility–the venture is backed by Y Combinator and Peak XV's Surge. "My sense is that less than a third of the market is truly organized, chained and branded. The remaining is mostly single-doctor or single-clinic practices," saidArjun Anand, managing director and head of Asia at global investment company Verlinvest. 'Startups that bring a positive differentiation to existing services of IVF & IUI will have an edge." Acquisition targets Verlinvest acquired a controlling stake in AP/Telangana-focused Ferty9 Fertility Centre in 2023. Large chains, too, are watching these startups as potential acquisition targets. Startups play a crucial role in bringing about innovative services that large players cannot possibly introduce at scale, making consolidation a favourable outcome. '...we are not only seeing much intense competition from large chains, but also seeing many new startups in this space," said Agarwal of Nova IVF, which was acquired by Asia Healthcare Holdings in 2019. The chain has 100 centres across the country, with over half of those in tier 2 and 3 cities, including Bareilly, Guwahati, and Vellore. Nova IVF is assessing acquisition opportunities in markets with low presence, said Agarwal. Last month, Economic Times reported, citing unnamed people, that US-based IVI RMA Global is set to acquire ART Fertility Clinics for $400-450 million. Indira IVF inked deals with Gujarat-based Banker Healthcare and Puducherry's Creation Science IVF in June as well. Birla Fertility & IVF acquired BabyScience IVF Clinics to expand its presence in southern and western India last year. Funding in the segment will continue to be driven by private equity investments, according to Verlinvest's Anand. 'Private equity brings scale, while venture capital fosters innovation. IVF is more suited to a private equity play as it's a centre-by-centre model and will take a linear curve to scale." Looking ahead On their part, the startups also continue to evolve to stay relevant. Luma Fertility is offering a more open and detailed analysis of diagnostic reports to its patients, besides investing in establishing a dedicated care team to guide them along the journey. 'For instance, our analysis of an AMH report states X-axis age, Y-axis AMH, where you are compared to the India average, and what this means for you, and what is your predictive decline," said CEO Motwani. 'The first place where the system is broken is how fertility assessment and testing are done. It needs to be more accessible, open, and with less judgment." Inito intends to be a pure-play product company, according to founder Rai. 'There is definite value in building hardware because at-home testing is largely under-penetrated. This segment can grow significantly, potentially outperforming top players in the product side." The startup also plans to foray into men's fertility with specialized products, which Rai termed an underrated topic. Nova IVF's Agarwal sees more opportunities including AI-driven embryo evaluation, genetic testing, newer therapies such as ovarian rejuvenation. "Any addition like a digital-first approach, more efficient tracking capabilities, and new technology will be valuable," saidVerlinvest's Anand. 'Better customer experience, the ability to cater to a premium audience, or a concierge service will help set a startup apart from traditional players." According to Bhanu Prakash Kalmath S J, partner and healthcare industry leader at Grant Thornton Bharat, 'what also matters is how you bring credibility through a better brand". This is what works for larger chains, which offer consistency and uniform services across centres, and that could work for new players as well, he said. Luma and Inito plan to carefully invest in expansion to maintain differentiation and sustainable economics. But Kalmath S.J. suggested that investing in technology to ensure compliance with regulations and complete data confidentiality is paramount too. More so, when big fertility treatment chains also look to protect their turf and stay ahead of the curve. As Sriram Iyer, CEO of Apollo Health and Lifestyle, which runs Apollo Fertility, explained: 'To stay competitive, investment in technology, prioritizing ethical practices, and addressing accessibility challenges are utmost."
Economic Times
25 minutes ago
- Economic Times
India VIX falls to 15-month low on no sharp market swings
Agencies Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Mumbai: Volatility Index or India VIX-the fear gauge of the Indian stock market-has dropped to its lowest level in 15 months, as the absence of sharp swings of late, a decline in US volatility, and falling derivatives options volumes have eased risk sentiment. The India VIX remained flat and ended at 11.2 on Thursday. The benchmark Nifty 50 index fell 100.60 points or 0.40% to close at 25,111."Indian markets are currently mirroring the US VIX, which is at a 7-8 month low, offering some relief to traders globally," said Ajit Mishra, senior vice-president, research, Religare Broking. "With limited domestic triggers and much of the earnings season already priced in, the index remains subdued."Since the start of July, Nifty has traded in a narrow 25,000-25,500 range, failing to break out in the absence of triggers. India VIX is a volatility index based on Nifty option prices. It uses the best bid-ask prices of Nifty options to calculate expected market volatility over the next 30 days. The index typically rises when traders expect bigger market swings and falls when markets appear the last month, India VIX is down almost 22%, whereas the benchmark Nifty 50 has edged up 1%. The Chicago Board Options Exchange's CBOE Volatility Index, which measures volatility based on US S&P 500 index options, is also down 19.7% over the past month. The drop in VIX could also be on account of a fall in trader participation in Nifty options."At first glance, this may seem like a sign of market confidence, but the reality points to suppressed hedging activity and reduced participation," said Dhupesh Dhameja, derivatives analyst, Samco Securities. "Traders have largely avoided buying deep out-of-the-money puts, keeping option premiums subdued and implied volatility low." Dhameja said reduced activity of global liquidity providers like Jane Street has led to lower derivative volumes and thinner option market depth, especially in far out-of-the-money contracts, which typically reflect macro risk VIX may not fully reflect what is happening across the market, as it tracks only the benchmark Nifty 50 and its large-cap constituents. "The market appears calm on surface, but history suggests that such low-volatility phases are often followed by sharp directional moves," said Dhameja. He said that for now, the trend may stay range-bound, but any spike in VIX could be a "signal worth watching closely."
&w=3840&q=100)
First Post
25 minutes ago
- First Post
In a win for Trump, US House passes three landmark cryptocurrency bills
Lawmakers easily approved the CLARITY Act, which aims to establish a clearer regulatory framework for cryptocurrencies and other digital assets. read more US House passes three landmark bills on Cryptocurrency. Reuters The US House of Representatives on Thursday passed three landmark cryptocurrency bills, fulfilling the Trump administration's commitment to the once-controversial industry. Lawmakers easily approved the CLARITY Act, which aims to establish a clearer regulatory framework for cryptocurrencies and other digital assets. The bill is designed to clarify industry rules and divide regulatory authority between the Securities and Exchange Commission (SEC) and the Commodity Futures Trading Commission (CFTC). It will now advance to the Senate, where Republicans hold a slim majority. STORY CONTINUES BELOW THIS AD House legislators also readily passed the GENIUS Act, which codifies the use of stablecoins – cryptocurrencies pegged to stable assets like the US dollar or US bonds. This bill is expected to go directly to President Trump for his signature to become law. The Senate passed the GENIUS Act last month, and it sets requirements such as mandating that issuers hold reserves of assets equal in value to their outstanding cryptocurrency. 'This historic legislation will bring our payment system into the 21st century. It will ensure the dominance of the US dollar. It will increase demand for US Treasuries,' said Senator Bill Hagerty, the measure's sponsor in the Senate. This wave of legislation follows years of skepticism towards crypto, driven by the belief that the sector, born from bitcoin's success, should be tightly controlled and kept separate from mainstream investors. However, after crypto investors contributed millions of dollars to his presidential campaign last year, Trump reversed his previous doubts about the industry. He even launched a Trump meme coin and other ventures as he prepared for his return to the White House and hosted a gala dinner for the coin's top buyers once he was in office. STORY CONTINUES BELOW THIS AD And according to the Financial Times, Trump is now preparing to open the $9 trillion US retirement market to cryptocurrency investments as well as gold, and private equity. Notably, both the CLARITY Act and the GENIUS Act garnered significant bipartisan support, with Democrats also having seen an increase in lobbying and contributions from the crypto industry. 'It's critically important we bring more certainty to the marketplace with clear rules of the road,' said congressman Josh Gottheimer, a Democrat who supported the bills. Since taking office, Trump has made several moves to support the crypto sector, including appointing crypto advocate Paul Atkins to lead the SEC. He also established a federal 'Strategic Bitcoin Reserve' to audit the government's bitcoin holdings, primarily accumulated through law enforcement's judicial seizures. Forbes magazine estimates that the president's foray into the crypto business has doubled his wealth to $5.3 billion in just one year. In a largely partisan vote, the Republican-led House also passed the Anti-CBDC Surveillance State Act. STORY CONTINUES BELOW THIS AD It aims to block the issuance of a central bank digital currency (CBDC) – a digital dollar issued by the US Federal Reserve – even if there currently are no plans for such an endeavor. Republicans argue that a CBDC could enable the federal government to monitor, track, and potentially control private citizens' financial transactions, thereby undermining privacy and civil liberties. Passage of this measure in the Senate is far from guaranteed before it can go to the president's desk. An earlier attempt to set aside the anti-CBDC bill caused a significant stir among a small group of Republicans and delayed passage of the other two bills until eleventh-hour lobbying by Trump helped resolve the issue.
